Moving to Specialty Drugs: Are You on Track?
Specialty pharmaceutical R&D and commercialization efforts are on the rise. Over the next five years, specialty drugs are expected to be the biggest drivers of branded drug spend growth, with investment projecting to increase 30%. Why the shift? Many reasons exist, from nearing patent cliffs to the ability to command higher pricing for these drugs. Additionally, there is oftentimes little to no competition for first movers in these niche disease states.
In Verix’s newest whitepaper, we detail why companies are shifting R&D towards specialty medicines – and what the payoff may be for those that do. We also explain the challenges around reimbursement, distribution and patient care – and how the sales and marketing model must evolve to support them. Finally, we review the rich datasets available – if you know to ask for them – and how you can use them to more effectively launch, market and sell your specialty drug.
Thinking about entering the specialty pharmaceutical space? Is your team ready?
Learn more by downloading our free whitepaper, Moving to Specialty Drugs: Are you on Track.